Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG CLASS:
FGFR inhibitor
DRUG CLASS:
FGFR inhibitor
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related drugs:
‹
lenvatinib (90)
erdafitinib (70)
infigratinib (53)
futibatinib (52)
pemigatinib (41)
ABSK091 (32)
BAY 1163877 (23)
Debio 1347 (17)
ARQ 087 (12)
TKI258 (9)
WXSH0011 (5)
ICP-192 (5)
CPL304110 (4)
E 3810 (4)
ABSK121 (3)
KIN-3248 (3)
AZ8010 (2)
E7090 (2)
MPT0L145 (1)
PRN1371 (1)
EOC317 (0)
SSR 128129 (0)
XL228 (0)
BAY 1179470 (0)
TAR-210 (0)
PI-88 (0)
TSU-68 (0)
SYHA1817 (0)
lenvatinib (90)
erdafitinib (70)
infigratinib (53)
futibatinib (52)
pemigatinib (41)
ABSK091 (32)
BAY 1163877 (23)
Debio 1347 (17)
ARQ 087 (12)
TKI258 (9)
WXSH0011 (5)
ICP-192 (5)
CPL304110 (4)
E 3810 (4)
ABSK121 (3)
KIN-3248 (3)
AZ8010 (2)
E7090 (2)
MPT0L145 (1)
PRN1371 (1)
EOC317 (0)
SSR 128129 (0)
XL228 (0)
BAY 1179470 (0)
TAR-210 (0)
PI-88 (0)
TSU-68 (0)
SYHA1817 (0)
›
Associations
(442)
News
Trials
Search handles
@AlbigesL
@AldoLADETTINO
@Amitmahipal79
@AndreaNecchi
@ArndtVogel
@AzadOncology
@BourlonMaite
@CathyEngMD
@ChungHanLee3
@DrBonillaOnc
@DrYukselUrun
@FaltasLab
@FogacciJoao
@GABOUALFA
@JavleMilind
@LorenzaRimassa
@MadisonConces
@NazliDizman
@NicoleKuderer
@OncoThor
@RenoHemonc
@RonenStoff
@SKamath_MD
@ShannonWestin
@SyedAAhmad5
@TiansterZhang
@VivekSubbiah
@anandoncologist
@antonyruggeri
@apolo_andrea
@bpiperdi
@carlosbon78
@davidhenrymd
@dr_yakupergun
@drenriquegrande
@jgong15
@kmody29
@koshkin85
@lindamahj
@marklewismd
@nataliagandur
@neerajaiims
@schoffski
@shilpaonc
@smreddymd
@sonpavde
@tnewsomdavis
@yekeduz_emre
Search handles
@AlbigesL
@AldoLADETTINO
@Amitmahipal79
@AndreaNecchi
@ArndtVogel
@AzadOncology
@BourlonMaite
@CathyEngMD
@ChungHanLee3
@DrBonillaOnc
@DrYukselUrun
@FaltasLab
@FogacciJoao
@GABOUALFA
@JavleMilind
@LorenzaRimassa
@MadisonConces
@NazliDizman
@NicoleKuderer
@OncoThor
@RenoHemonc
@RonenStoff
@SKamath_MD
@ShannonWestin
@SyedAAhmad5
@TiansterZhang
@VivekSubbiah
@anandoncologist
@antonyruggeri
@apolo_andrea
@bpiperdi
@carlosbon78
@davidhenrymd
@dr_yakupergun
@drenriquegrande
@jgong15
@kmody29
@koshkin85
@lindamahj
@marklewismd
@nataliagandur
@neerajaiims
@schoffski
@shilpaonc
@smreddymd
@sonpavde
@tnewsomdavis
@yekeduz_emre
Filter by
Latest
8ms
Results from the phase 1b/2 #FIDES02 study: Derazantinib for metastatic #BladderCancer with activating FGFR1/2/3 genetic aberrations. @AndreaNecchi @SanRaffaeleMI joins @CaPsurvivorship @DanaFarber to discuss on UroToday > https://t.co/7XkvtuwvBN (@urotoday)
8 months ago
Metastases
|
FGFR1 (Fibroblast growth factor receptor 1)
|
derazantinib (ARQ 087)
8ms
Insightful discussion with @y_loriot on the randomized #THOR study data that he presented at #ASCO23, confirming efficacy of Erdafitinib in FGFR3-altered platinum-refractory patients with #BladderCancer @ASCO @BladderCancerUS @IBCG_BladderCA @onclive @Uromigos (@koshkin85)
8 months ago
Clinical
|
FGFR3 (Fibroblast growth factor receptor 3)
|
Balversa (erdafitinib)
8ms
Lenvatinib plus pembrolizumab demonstrated improved ORR compared with sunitinib monotherapy in treatment-naïve patients with advanced RCC regardless of risk status or PD-L1 expression. @motzermd @MSKCancerCenter @kidneycan #KCRS23 #kcsm https://t.co/p1LcSl5Czk (@OncLive)
8 months ago
Clinical • IO biomarker • Metastases
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression
|
Keytruda (pembrolizumab) • Sutent (sunitinib) • Lenvima (lenvatinib)
8ms
Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in HCC @OncologyAdvance https://t.co/xit1v39BjF ❓What should we do and what can we expect for 2nd line therapy 🌍RWD suggest: 👉AtzeBev > Lenva 👉Lenva > ICI @myESMO @ILCAnews @EASLedu… https://t.co/ALX315Novm (@ArndtVogel)
8 months ago
Clinical
|
Avastin (bevacizumab) • Tecentriq (atezolizumab) • Lenvima (lenvatinib)
8ms
According to data from the final OS analysis of the CLEAR study, lenvatinib plus pembrolizumab produced an ORR of 71.3% in treatment-naïve patients with advanced RCC vs 36.7% with sunitinib. @motzermd @MSKCancerCenter @kidneycan #KCRS23 #kcsm https://t.co/NDvc1gD1Ne (@OncLive)
8 months ago
Clinical • Metastases
|
Keytruda (pembrolizumab) • Sutent (sunitinib) • Lenvima (lenvatinib)
8ms
🔘 Resistance to selective FGFR inhibitors in FGFR-driven urothelial cancer #bladdercancer @AACR https://t.co/m6KtQXHHYf (@drenriquegrande)
8 months ago
8ms
In patients with FGFR-mutant urothelial cancer (UC), after immune checkpoint progression, do you use enfortumab vedotin (EV) or erdafitinib ? #ACScancerchat https://t.co/F6nmlNDAh5 (@VivekSubbiah)
8 months ago
Clinical
|
FGFR (Fibroblast Growth Factor Receptor)
|
FGFR mutation
|
Balversa (erdafitinib) • Padcev (enfortumab vedotin-ejfv)
8ms
15a/16 #TumorBoardTuesday 🧑🏼🔬Ongoing Trials assessing belzutifan in sporadic met #RCC ✨Pembro+lenva: https://t.co/RseK3omjaO ✨Belzu+pembro v placebo+pembro: https://t.co/UIZCuOHgoR ✨Pembro+belzu+lenva OR pembro/Quavo+lenva v pembro+lenva https://t.co/QTUdhDsyb9 (@katy_beckermann)
8 months ago
Clinical
|
Keytruda (pembrolizumab) • Lenvima (lenvatinib) • Welireg (belzutifan)
9ms
🗞️ Published in @TheLancetOncol and co-authored by VHIO’s @crisuarez08, results from the single-arm phase II KEYNOTE-B61 clinical trial support the use of pembrolizumab plus lenvatinib in patients with previously untreated advanced non-clear cell renal cell carcinoma. ➕… https://t.co/qUn891LZBA (@VHIO)
9 months ago
Clinical • Metastases
|
Keytruda (pembrolizumab) • Lenvima (lenvatinib)
9ms
Lenvatinib/Pembrolizumab Benefit Is Upheld in Advanced RCC, Including ICI-Pretreated and Naïve Subgroups @ChungHanLee3 @MSKCancerCenter @kidneycan #KCRS23 #kcsm https://t.co/yU9CWV30fx (@OncLive)
9 months ago
Metastases
|
Keytruda (pembrolizumab) • Lenvima (lenvatinib)
9ms
Frontline Lenvatinib Plus Pembrolizumab Produces Superior Responses Vs Sunitinib in Advanced RCC @motzermd @MSKCancerCenter @kidneycan #KCRS23 #kcsm https://t.co/RQML5zNQnC (@OncLive)
9 months ago
Metastases
|
Keytruda (pembrolizumab) • Sutent (sunitinib) • Lenvima (lenvatinib)
9ms
The sustained OS benefit observed with pembrolizumab and lenvatinib in the CLEAR study solidifies the doublet’s use as a preferred option for the frontline treatment of patients with advanced RCC. @DrTHut @TexasOncology @SarahCannonDocs #kcsm https://t.co/Jmjj0bMNuC (@OncLive)
9 months ago
Clinical • Metastases
|
Keytruda (pembrolizumab) • Lenvima (lenvatinib)
9ms
Guess who stopped by? @ChungHanLee3, of @MSKCancerCenter! Thanks for speaking with us about the final results of the phase 2 cohort of lenvatinib + pembrolizumab for progressive disease after a PD-1/PD-L1-containing therapy in metastatic clear cell RCC #kcsm @kidneycan (@OncLive)
9 months ago
Clinical • P2 data • Metastases
|
Keytruda (pembrolizumab) • Lenvima (lenvatinib)
9ms
We spoke with @ChungHanLee3 from @MSKCancerCenter on the use of lenvatinib and pembrolizumab in patients with RCC. #kicsm | @kidneycan (@CancerNetwrk)
9 months ago
Clinical
|
Keytruda (pembrolizumab) • Lenvima (lenvatinib)
9ms
Encouraging results in non-clear cell RCC. However, efficacy appears to be lower in the chromophobe subtype and in the PDL1-negative group. In the chromophobe type, lenvatinib + everolimus may be more effective. (@dr_yakupergun)
9 months ago
Clinical
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 negative
|
everolimus • Lenvima (lenvatinib)
9ms
⭐️KEYNOTE-B61 single-arm, ph 2 trial of first-line pembrolizumab plus lenvatinib for advanced non-clear-cell renal cell carcinoma, 78 of 158 patients had a confirmed objective response (49%; 95% CI 41–57) @TheLancetOncol @OncoAlert @AlbigesL https://t.co/59ZG4tZHVI (@VivekSubbiah)
9 months ago
Clinical • Metastases
|
Keytruda (pembrolizumab) • Lenvima (lenvatinib)
9ms
After a great presentation at @ASCO #ASCO23, full paper just out @TheLancetOncol Keynote B61: 🚹Non-clear cell mRCC 💊Pembrolizumab+Lenvatinib 1st line 🎯ORR:49%, CR:6% @DrChoueiri @AlbigesL @ChungHanLee3 @OncoAlert @DrYukselUrun https://t.co/pHrrelHSLb (@yekeduz_emre)
9 months ago
Keytruda (pembrolizumab) • Lenvima (lenvatinib)
9ms
Pleased to share @TheLancetOncol LENVA-PEMBRO across RCC variant histologies: papillary RCC, unclRCC and chromophobe RCC … interim @myESMO #ESMO22 and final @ChungHanLee3 @ASCO #ASCO23 full text: https://t.co/QioxQEiKho Thanks to all who change rareRCC pts Tx! (@AlbigesL)
9 months ago
Clinical
|
Keytruda (pembrolizumab) • Lenvima (lenvatinib)
9ms
WATCH: @sonpavde, of @DanaFarber, discusses the potential impact of the phase 3 THOR study evaluating erdafitinib vs chemotherapy in patients with advanced or metastatic urothelial cancer harboring FGFR2/3 alterations. #oncology #medtwitter https://t.co/UFawzLBrGJ (@OncLive)
9 months ago
Clinical • Metastases
|
FGFR2 (Fibroblast growth factor receptor 2)
|
Balversa (erdafitinib)
9ms
Long-Term OS Data Confirm Pembrolizumab/Lenvatinib as a Primary Frontline Option in Advanced RCC @DrTHut @TexasOncology @SarahCannonDocs #kcsm https://t.co/4CP5RKH4Vq (@OncLive)
9 months ago
Metastases
|
Keytruda (pembrolizumab) • Lenvima (lenvatinib)
9ms
Lenvatinib plus pembrolizumab showed a sustained overall survival and progression-free survival benefit vs sunitinib alone at a median follow-up of 4 years in patients with advanced renal cell carcinoma. @DrTHut @bswhealth https://t.co/2uj87xQ7pv (@OncLive)
9 months ago
Clinical • Metastases
|
Keytruda (pembrolizumab) • Sutent (sunitinib) • Lenvima (lenvatinib)
9ms
🎥@ArndtVogel discusses the latest developments in FGFR inhibition in hepatobiliary cancer. Pemigatinib and futibatinib show promise in cholangiocarcinoma, and RLY-4008 offers reduced toxicity: ➡️https://t.co/Fk9WqYbQcp⬅️ #WCGIC23 @myESMO #HPBCsm (@VJOncology)
9 months ago
Lytgobi (futibatinib) • Pemazyre (pemigatinib) • lirafugratinib (RLY-4008)
9ms
European Commission Grants Conditional Marketing Authorization for Futibatinib for the Treatment of Adults With Cholangiocarcinoma - @ArndtVogel #cancer #cancercare #drugs #futibatinib #cholangiocarcinoma #oncology #oncodaily https://t.co/m4FxYyxVv3 (@oncodaily)
9 months ago
European regulatory
|
Lytgobi (futibatinib)
9ms
European Commission Grants Conditional Marketing Authorization for Futibatinib for the Treatment of Adults With #Cholangiocarcinoma 😅Finally, good news for our patients in Europe as well 👉Efficacy demonstrated in FOENIX-CCA2 @myESMO @EASLnews @ILCAnews @OncoAlert #livertwitter (@ArndtVogel)
9 months ago
Clinical • European regulatory
|
Lytgobi (futibatinib)
9ms
Lenvatinib plus pembrolizumab showed a sustained overall survival and progression-free survival benefit vs sunitinib alone at a median follow-up of 4 years in patients with advanced renal cell carcinoma. @DrTHut @bswhealth https://t.co/PJMI5i2fqE (@OncLive)
9 months ago
Clinical • Metastases
|
Keytruda (pembrolizumab) • Sutent (sunitinib) • Lenvima (lenvatinib)
9ms
Lenvatinib Plus Pembrolizumab vs Regorafenib or TAS for Previously Treated mCRC: Phase 3 LEAP-017 Study at #WCGIC2023 👉mOS: 9.8 vs 9.3 mo 👉There is some activity, but⛔️ 👉IO in MSS CRC remains a challenge... @WCGIC @myESMO @OncoAlert (@ArndtVogel)
9 months ago
P3 data
|
Keytruda (pembrolizumab) • Lenvima (lenvatinib) • Stivarga (regorafenib)
9ms
FGFR inhibition in #urothelialcarcinoma #bladdercancer at #ASCO23 - 1)The THOR Phase III trial in advanced #urothelialcarcinoma (UC) with FGFR2/3 mutations/fusions: Erdafitinib extended overall survival (OS) v taxane or vinflunine chemotherapy (median 12.1 v 7.8 mo, HR 0.64,… https://t.co/AM7hNC5Db6 (@sonpavde)
9 months ago
Clinical • Metastases
|
FGFR2 (Fibroblast growth factor receptor 2)
|
FGFR2 mutation • FGFR2 fusion
|
Balversa (erdafitinib) • Javlor (vinflunine)
9ms
Futibatinib in Patients With FGFR2-Rearranged Intrahepatic CCA: Responder Analyses of Efficacy & Safety From the Phase 2 FOENIX-CCA2 Study at #WCGIC2023 😅no surprises: Longer PFS & OS for responders 👉no clear impact of co-alterations @WCGIC @myESMO @EASLedu @ILCAnews @curecc https://t.co/b2vCSEexVo (@ArndtVogel)
9 months ago
Clinical
|
FGFR2 (Fibroblast growth factor receptor 2)
|
Lytgobi (futibatinib)
9ms
Results from the phase 1b/2 #FIDES02 study: Derazantinib for metastatic #BladderCancer with activating FGFR1/2/3 genetic aberrations. @AndreaNecchi @SanRaffaeleMI joins @CaPsurvivorship @DanaFarber to discuss on UroToday > https://t.co/7XkvtuwvBN (@urotoday)
9 months ago
Metastases
|
FGFR1 (Fibroblast growth factor receptor 1)
|
derazantinib (ARQ 087)
9ms
Thank you @CancerTherAdvsr for featuring our article on HRQOL outcomes w 2 different starting doses of lenvatinib in combination w everolimus for previously treated RCC Grateful for this opportunity @montypal @OncJournal @DrDanielHeng @docjavip @cdanicas https://t.co/eJ3z4eA5oq (@crisbergerot)
9 months ago
everolimus • Lenvima (lenvatinib)
9ms
Open label phase-2 trial of Futibatinib in advanced gastric cancer with FGFR2 amplification and at least two prior systemic regimens for advanced/metastatic disease. Modest results: ORR 17.9%, DCR 50%, mDoR 3.9 m, mPFS 2.8 m, mOS 5.7 months #WCGIC2023 (@carlosbon78)
9 months ago
Clinical • P2 data • Metastases
|
FGFR2 (Fibroblast growth factor receptor 2)
|
FGFR2 amplification
|
Lytgobi (futibatinib)
9ms
At #ASCO23, @y_loriot discussed the latest data from the THOR study, which compared #erdafitinib and chemotherapy in patients with advanced or metastatic urothelial cancer with select fibroblast growth factor receptor alterations. Watch now: https://t.co/nYfEnwGfpx (@GUOncologyNow)
9 months ago
Clinical • Metastases
|
FGFR (Fibroblast Growth Factor Receptor)
|
Balversa (erdafitinib)
9ms
Pembro & Lenvatinib can be challenging: Was there any toxicity data? Worried about this in a relapsed mesothelioma patient group (@tnewsomdavis)
9 months ago
Clinical
|
Keytruda (pembrolizumab) • Lenvima (lenvatinib)
9ms
At @ASCO23, @DrRanaMcKay met with @ChungHanLee3 to discuss the latest data on KEYNOTE-B61 for first-line #lenvatinib plus pembrolizumab for non-clear cell renal cell carcinoma. Watch now: https://t.co/awjZeCxkRb (@GUOncologyNow)
9 months ago
Clinical
|
Keytruda (pembrolizumab) • Lenvima (lenvatinib)
9ms
Glad to discuss the options for #FGFR inhibition in the management of #cholangiocarcinoma #CCA #biliarytractcancer with @DrAngelaLamarca and @ArndtVogel @HUNIMED @HumanitasMilano @PeerVoice (@LorenzaRimassa)
9 months ago
9ms
In the PROOF 302 trial, @PGrivasMDPhD and colleagues sought to determine the efficacy and safety of the FGFR1-3 inhibitor #infigratinib against placebo in patients with high-risk invasive urothelial carcinoma. Learn more about the results of the study: https://t.co/AJU7GErAcm (@GUOncologyNow)
9 months ago
Clinical
|
Truseltiq (infigratinib)
9ms
The therapeutic landacape of #bladdercancer has changed!! ✅ Patients w FGFR alterations can be treated w erdafitinib 👩🏻🔬🏨🧬 🔹Phosphorus needed for dose titration 🫙 🔹Skin, nails & 👁️ toxicity!!! 🔹High disease control rate @EvelynBeas2 @Yuly_Remo @DrFrancas @TomFlaigMD https://t.co/w8Fh8RH3E9 (@BourlonMaite)
9 months ago
Clinical
|
FGFR (Fibroblast Growth Factor Receptor)
|
Balversa (erdafitinib)
9ms
Arlene O. Siefker-Radtke, MD, from @MDAndersonNews, spoke with @koshkin85 while at #ASCO23 on the the phase 2 NORSE study on the use of erdafitinib with or without cetrelimab in patients with metastatic urothelial carcinoma and FGFR alterations. Watch now: https://t.co/yx7gSuKsAE (@GUOncologyNow)
9 months ago
Clinical • Metastases
|
FGFR (Fibroblast Growth Factor Receptor)
|
Balversa (erdafitinib) • cetrelimab (JNJ-63723283)
9ms
Honored to present #bladdercancer highlights from #ASCO23 @VuMedi- the most important new data in my judgment: 1) THOR Phase III trial-Erdafitinib extended overall survival (OS) v taxane or vinflunine chemo (median 12.1 v 7.8 mo, HR 0.64, p=0.005) in advanced #urothelialcarcinoma… https://t.co/T8Dz9iCSAo (@sonpavde)
9 months ago
Clinical • Metastases
|
Balversa (erdafitinib) • Javlor (vinflunine)
9ms
#EGFR inhibition potentiates FGFR inhibitor therapy and overcomes resistance in FGFR fusion-positive advanced #cholangiocarcinoma https://t.co/jBV3Ozice5 #fondazionebonadonna #cancerresearch #oncology @CarmenCriscit @BianchiniGP @mauricallari (@FondazioneBona1)
9 months ago
Metastases
|
FGFR fusion
10ms
4/10 Also promising @ASCO research on HRR gene alterations in #prostatecancer, FGFR inhibition in #bladdercancer, and HER2 therapy across cancer types. This was just the tip of the iceberg in terms for the expanded impact across disease types! https://t.co/tlsX7SBP7Q (@geoff_oxnard)
10 months ago
HRD (Homologous Recombination Deficiency)
10ms
What may also be relevant to GI cancers is the simultaneous Cancer Discovery publication at @ASCO #ASCO23 of RLY-4008- the first highly selective FGFR2 inhibitor with activity across FGFR2 alterations and resistance mutations with the clinical science symposium @CD_AACR with… https://t.co/YUjSUPRVYK (@VivekSubbiah)
10 months ago
Clinical
|
FGFR2 (Fibroblast growth factor receptor 2)
|
FGFR2 mutation
|
lirafugratinib (RLY-4008)
Share
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login